医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Queensland’s Metro North Hospital and Health Service Reduces Costs and Improves Patient Care With Nutanix

2017年09月06日 AM08:00
このエントリーをはてなブックマークに追加


 

SYDNEY

Nutanix (NASDAQ: NTNX), a leader in enterprise cloud computing, today announced that Queensland’s largest public hospital and health service, Metro North Hospital and Health Service, has deployed the Nutanix Enterprise Cloud Platform, helping it to reduce costs and develop new digital services to improve patient care and the flexibility of delivering clinical information systems.

Metro North Hospital and Health Service (MNHHS) comprises five hospitals including Royal Brisbane and Women’s Hospital, The Prince Charles Hospital, Redcliffe, Caboolture and Kilcoy Hospitals in Brisbane’s north and treats more than 600,000 patients annually.

Metro North’s Solutions Architect Antony Batrouni said the consolidation meant going from four data centres to one highly resilient primary site with a remote disaster recovery site.

“We needed something that could scale quickly to meet the demands of a much larger organisation, and that’s when we selected Nutanix,” Mr Batrouni said.

The additional IT capability achieved with Nutanix has enabled a commensurate platform for digital services to be implemented within the hospital group. It deployed the MNHHS electronic Referral Management system and Enterprise Service Bus, which will be extended for broader clinical services in the near term. These systems require high performance and availability as expected by clinical services.

Mr Batrouni said the types of systems the HHS was launching now were more complex than ever before, with a DevOps team focused on developing innovative services for clinicians to enable them to provide better care to patients.

“Nutanix ensures these services are reliable and can be turned into a platform faster than ever before,” Mr Batrouni said.

Nutanix has also enabled Metro North to make significant cost savings in database management systems (DBMS) licensing fees and a total reduction in cost of almost 50 per cent per virtual machine (VM) deployed.

“In a hospital environment, any cost savings made in areas such as IT are then available to be invested back into patient care,” Mr Batrouni said.

With the Nutanix platform, MNHHS is looking to new technology to bring additional services to benefit patients, such as advanced medical imaging. Overall, the platform has led to increased performance, higher availability and improved disaster recovery design across the 800 applications used daily by staff. The platform is supporting around four times its previous workload and with additional capacity to spare. This means a better user experience and mitigated impact to clinical staff and patients if there are any outages or other issues.

Nutanix was selected by Metro North primarily due to its maturity and leadership in the enterprise cloud and hyperconverged infrastructure space, as well as its compatibility with Dell. The organisation has incrementally increased its environment since the initial deployment and uses virtually all Nutanix’s products and services. It is considering using the Nutanix hypervisor AHV in the near future.

“Health organisations and the patients they care for can gain huge benefits from digital transformation,” said Matt Young, Senior Vice President and Head of APJ, Nutanix. “To realise that potential, you need the right infrastructure in place to manage it. Metro North is using enterprise cloud technology to save costs and develop digital services that have real benefits for clinicians and patients.”

About Nutanix

Nutanix makes infrastructure invisible, elevating IT to focus on the applications and services that power their business. The Nutanix Enterprise Cloud Platform leverages web-scale engineering and consumer-grade design to natively converge compute, virtualisation and storage into a resilient, software-defined solution with rich machine intelligence. The result is predictable performance, cloud-like infrastructure consumption, robust security, and seamless application mobility for a broad range of enterprise applications. Learn more at www.nutanix.com or follow us on Twitter @nutanix.

Forward Looking Statements Disclaimer

This press release includes forward-looking statements, including but not limited to statements concerning our relationship with Queensland Health Metro North and its expected purchases of our products in the future. These forward-looking statements are not historical facts, and instead are based on our current expectations, estimates, opinions and beliefs. The accuracy of such forward-looking statements depends upon future events, and involves risks, uncertainties and other factors beyond our control that may cause these statements to be inaccurate and cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by such statements, including, among others: failure to develop, or unexpected difficulties or delays in developing, new product features or technology on a timely or cost-effective basis; the introduction, or acceleration of adoption of, competing solutions, including public cloud infrastructure; a shift in industry or competitive dynamics or customer demand; adoption of new, or changes to existing, international laws and regulations; and other risks detailed in our quarterly report on Form 10-Q for the fiscal quarter ended April 30, 2017, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release and, except as required by law, we assume no obligation to update forward-looking statements to reflect actual results or subsequent events or circumstances.

© 2017 Nutanix, Inc. All rights reserved. Nutanix, the Enterprise Cloud Platform and the Nutanix logo are registered trademarks or trademarks of Nutanix, Inc. in the United States and other countries. All other brand names mentioned herein are for identification purposes only and may be the trademarks of their respective holder(s).

View source version on businesswire.com: http://www.businesswire.com/news/home/20170905005913/en/

CONTACT

Nutanix
Luica Mak, +44 790 547 1332
luica.mak@nutanix.com
or
Watterson
(for Nutanix)
Oisin O’Callaghan, +61 2 9929 7533 or +61 431 612 386
oisin.ocallaghan@watterson.com.au

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • SCIEX and NUS Faculty of Science Announce Plans to Launch New Training Centre for Proteomics and Mass Spectrometry Across Asia Pacific
  • Puma Biotechnology and Specialised Therapeutics Asia Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Australia, New Zealand and South East Asia
  • Preceptis Medical宣布面向中国的B轮融资和全球增长战略
  • オクタファルマ、開発途上国の血友病患者を治療するために当社のNuwiq製剤3050万国際単位を寄付
  • Octapharma捐赠3050万国际单位该公司药品 Nuwiq以治疗发展中国家的血友病患者